By Upal Basu Roy, MPH, PhD, Senior Director of Research, February 4, 2019
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, comprising 85% of all diagnosed cases of lung cancer. Treatment of NSCLC is dependent on the stage of the disease. In stage III NSCLC, the primary (original) tumor is large and the cancer has spread to lymph nodes in the center of the chest or other lymph nodes that are on the same side as the primary tumor. This stage of NSCLC is often referred to as locally advanced lung cancer and is divided into stages IIIA, IIIB, and IIIC, based on which lymph nodes have been affected and the size of the primary tumor. (Read...
By Juhi Kunde, MA, LUNGevity Science Writer, January 29, 2019
In 2004, after the discovery of mutations in the EGFR gene in lung cancer, the FDA approved a targeted therapy that increased survival in EGFR-positive NSCLC patients. However, the tumors inevitably became resistant to the treatment, and the cancer returned unchecked.
To understand what was causing the cancer to come back, researchers studied the genomic changes in the tumors that had recurred. What they found was surprising! Tumor cells are shrewd—they were developing additional mutations that allowed the tumor to survive and thrive. Researcher developed new drugs (third-generation...
By Upal Basu Roy, MPH, PhD, Senior Director of Research, January 14, 2019
At LUNGevity, we are incredibly excited to welcome 2019 and see what advances this new year will bring! As we look forward, it’s important to remember all the advancements that 2018 brought us.
2018 was an exciting year: the US Food and Drug Administration (FDA) approved 8 new treatment approaches for lung cancer (of which 4 are biomarker-driven), PhRMA listed 132 new treatment approaches for lung cancer in development, and results of the Nelson trial on lung cancer screening in Europe were disclosed.
By Juhi Kunde, MA, LUNGevity Science Writer, November 26, 2018
Small cell lung cancer (SCLC) accounts for about 15% of all lung cancers and is found most often in people with a history of tobacco exposure. Patients with late-stage SCLC often respond so well to initial treatments that the cancer usually regresses and can even become undetectable in some cases. Unfortunately, in the vast majority of these cases, the cancer soon returns aggressively and is then resistant to treatment.
Jonathan Lehman, MD, PhD, is a medical oncologist and lung cancer researcher at Vanderbilt University Medical Center who has seen firsthand the limited treatments...